On March 27, 2026, Novartis announced an agreement to acquire Excellergy, Inc., a private biotech firm specializing in next-generation anti-IgE therapies. The deal, valued at up to $2 billion, aims to optimize the treatment of IgE-driven diseases such as food allergies, asthma, and chronic urticaria.
Key highlights of the acquisition:
-
Strategic Asset Exl-111: The centerpiece is Exl-111, a high-affinity, half-life extended anti-IgE antibody currently in Phase 1 trials. Unlike conventional approaches, Exl-111 is designed to dissociate receptor-bound IgE, driving faster and deeper suppression of the allergic pathway.
-
Enhanced Patient Outcomes: With its extended half-life design, Exl-111 holds the potential to deliver sustained symptom control and more convenient dosing intervals for patients, including pediatric populations.
-
Strengthening Immunology Leadership: This acquisition leverages Novartis’ deep expertise in IgE biology, perfectly complementing its existing allergy portfolio to address the rising global burden of allergic diseases.
-
Transaction Details: Novartis will provide upfront and milestone-based payments. The transaction is expected to close in the second half of 2026, subject to customary closing conditions and regulatory approvals.
This move underscores Novartis’ strategy of advancing bold science to bring meaningful additional benefits to patients living with autoimmune and allergic conditions.